# Krka account plan

> Krka is a Slovenian vertically integrated generic pharmaceutical group: 2025 revenue €2,041.0 million, 13,236 employees, sales in over 70 countries.

## At a glance

Krka, d. d., Novo mesto (founded 1954, listed on the Ljubljana Stock Exchange) is a vertically integrated generic pharmaceutical group that controls R&D, API and finished-product manufacturing, and marketing and sales through its own network. It sells prescription and non-prescription medicines, animal health products and health resort services to wholesalers, hospitals and pharmacies; over 100 million people use its products in over 70 countries, and markets outside Slovenia are 94% of sales. In 2025 revenue was €2,041.0 million (+7%), EBITDA €558.7 million (27.4% margin) and net profit €403.7 million (+13%). It had 13,236 employees at year-end 2025, 42% outside Slovenia, and has no non-current borrowings.

## Business units

- **Prescription pharmaceuticals** (83.2% of 2025 sales (€1,691.7 million)): Medicines mainly for chronic diseases, with cardiovascular agents the largest class, plus central nervous system, gastrointestinal, pain relief and antidiabetic medicines. Sales rose 10% to €1,396.6 million in January–September 2026, led by the Russian Federation, Ukraine and Hungary.
- **Non-prescription products** (8.5% of 2025 sales (€173.5 million)): Cough and cold products, analgesics and vitamins under brands such as Septolete, Nalgesin, Herbion and Septanazal, sold mainly in central, eastern and south-eastern Europe. Sales fell 4% in January–September 2026 on a mild flu season.
- **Animal health products** (5.6% of 2025 sales (€114.7 million)): Mostly companion-animal products such as Milprazon, Fypryst and Selehold, plus farm-animal products. Sales rose 7% to €95.0 million in January–September 2026.
- **Health resort and tourist services (Terme Krka)** (2.7% of 2025 sales (€54.2 million)): Spas and hotels in Slovenia, including Terme Dolenjske Toplice, Terme Šmarješke Toplice, Hoteli Otočec and Talaso Strunjan, with 353,745 overnight stays in 2025.

## Strategic priorities

- **2026–2030 growth and margin targets**: At least 5% average annual sales growth, an average EBITDA margin of at least 25% and at least 50% of net profit paid as dividends, with a top-5 generic position in all traditional markets.
- **Single-pill combinations**: More than 200 combination medicines launched, over 30% of total sales; management credits product mix as the main driver of the margin gain.
- **New therapeutic areas**: Entry into heart failure and obesity, plus complex formulations and peptide-based products; about 170 projects in development.
- **R&D at 10% of revenue**: Allocate 10% of revenue to R&D, with more than 800 in-house experts; about 60% of R&D spend goes to new products and 40% to lifecycle management.
- **Supply reliability and global capacity**: Treat supply reliability as a strategic asset and globalise capacity through joint ventures in India and China, with an average €150 million a year for capacity and infrastructure.
- **Digitalisation and automation**: Accelerated digitalisation and automation, including artificial intelligence tools; an R&D digitalisation strategy for 2026–2030 was prepared.

## Latest results

In January–September 2026 revenue rose 8% to €1,660.0 million, with 94% of sales outside Slovenia. Profitability grew faster: EBITDA rose 21% to €527.9 million (margin 31.8%), EBIT 24% to €455.5 million and net profit 13% to €364.2 million, as cost of goods sold stayed flat at €650.2 million. Region East Europe grew 14% to €606.7 million, led by the Russian Federation (+18%), while Region West Europe fell 2%. The 2026 estimate was raised to revenue of €2,179 million and net profit of €439 million, and the 2027 plan targets €2,308 million revenue and €474 million net profit.

## Investments and deals

- **India joint venture with Laurus Labs**: Krka holds 51% of Krka Pharma Private Limited in Hyderabad; completion is now targeted by the end of 2027, adding about 3 billion tablets a year of capacity.
- **Slovenian plant upgrades**: Investments of €87.3 million in January–September 2026 (+31%): Notol and Notol 2 upgrades, a sterile solutions line extension, a high-bay warehouse at Ljutomer and veterinary capacity at Bršljin.
- **Capex plan**: 2026 capex is now around €115 million because permits took longer; €141 million is planned for 2027.
- **Share buybacks and dividends**: Dividend of €9.1 per share, the 27th consecutive increase; €31 million of buybacks in 9M 2026 and a new 3-year buyback programme for cancellation.

## Challenges and risks

- **Rouble exposure**: Foreign exchange risk is the only risk rated High: the long rouble position cannot be hedged with suitable instruments, and it produced a €9.7 million loss in 9M 2026.
- **Price erosion and raw materials**: Management names price erosion, rising raw material prices, exchange rates and lower demand as risks to the plan.
- **Weak West Europe**: Region West Europe sales fell 2% in 9M 2026, with declines in Italy, Spain, France, Belgium and the Netherlands.
- **Supply chain and quality risks**: Supply of APIs and finished products, quality management, IT disruption and workforce availability are rated moderate risks.

## What leadership says

> "We are not only growing but growing more profitably." — David Bratož, Member of the Management Board, Krka Group 1–9 2026 results webcast, 13 November 2026

> "Profitability remains a top priority. We don't chase sales at the cost of margins." — David Bratož, Member of the Management Board, FY 2025 preliminary results webcast, 29 January 2026

> "The Krka Group continues to be financially stable, is not dependent on debt financing, provides its shareholders with an attractive return, and maintains its independent path of development." — Jože Colarič, President and CEO, Annual Report 2025, April 2026


## Where a supplier can help

- **Manufacturing automation and packaging**: Tied to the plant upgrades and digitalisation priority: robotic cells, packaging lines and automated warehouses are already being bought for Notol and Ljutomer.
- **Capacity build-out in India**: Tied to the India joint venture: equipment, engineering and validation suppliers for a site adding about 3 billion tablets a year.
- **Supply chain and quality systems**: Tied to the supply reliability priority and the supply and quality risks: planning, serialisation and quality-management tools across a multi-site network.
- **R&D and regulatory digitalisation**: Tied to the R&D at 10% of revenue priority and the R&D digitalisation strategy: tools that speed development and the high volume of registration procedures.
- **Sales force effectiveness**: Tied to the growth targets: Krka relies on more than 4,000 medical representatives, so CRM and field-force analytics support top-5 positions in its markets.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Krka Group and Krka Annual Report 2025](https://www.krka.biz/_assets/KRKA_LetnoPorocilo2025_ANG_.pdf)

Annual report · 2026-04-09

- Krka (Novo mesto, Slovenia) is a vertically integrated generic pharmaceutical group: it controls R&D, API and finished-product manufacturing, marketing and sales; over 100 million people use its products in over 70 countries, and exports are 94% of sales.
- 2025 was a record year: revenue €2,041.0 million (+7%, first time above €2 billion), EBITDA €558.7 million (27.4% margin), EBIT €465.1 million, net profit €403.7 million (+13%), ROE 17.5%; product sales volume +5%.
- Prescription pharmaceuticals are 83.2% of sales (€1,691.7 million, +8%), non-prescription products 8.5% (€173.5 million), animal health 5.6% (€114.7 million), health resort and tourist services (Terme Krka) 2.7% (€54.2 million).
- Region East Europe is the largest region (€713.4 million, 35.1%); the Russian Federation is the largest single market (€422.3 million, +13%), followed by Poland (€230.1 million, +12%).
- 2026–2030 strategy: at least 5% average annual sales growth, at least 25% average EBITDA margin, 10% of revenue to R&D, €150 million average annual capex, at least 50% of net profit paid as dividends, top-5 generic company in all traditional markets.
- Combination (single-pill) medicines are the core innovation: over 150 in the portfolio; products launched in the last five years were 29% of sales; about 170 projects in development; new areas are heart failure and obesity, plus complex peptide-based products.
- Debt-free, with no non-current borrowings; foreign exchange risk (mainly the Russian rouble, which cannot be hedged with suitable instruments) is the only risk rated High.
- 2026 plan: €2.132 billion sales, €405 million net profit, investments of €141 million (over €140 million), headcount up 2% from 13,236; a joint venture plant with Laurus Labs in Hyderabad, India, is due to be completed by end-2026.

### [January to September 2026 Unaudited Interim Report of the Krka Group and Krka](https://www.krka.biz/_assets/January-to-September-2026-unaudited-interim-report-of-the-Krka-group-and-Krka.pdf)

Interim report · 2026-11-12

- Krka Group revenue for January–September 2026 was €1,660.0 million (+8%); 94% of product and service sales came from outside Slovenia.
- Profitability jumped: EBIT €455.5 million (+24%, margin 27.4%), EBITDA €527.9 million (+21%, margin 31.8%), net profit €364.2 million (+13%, margin 21.9%); cost of goods sold was flat at €650.2 million, 39.2% of revenue.
- Region East Europe grew 14% to €606.7 million (36.7% of sales), led by the Russian Federation (€372.1 million, +18%) and Ukraine (€82.7 million, +14%); Region West Europe fell 2% to €266.8 million.
- Prescription pharmaceuticals rose 10% to €1,396.6 million (84.5% of sales); non-prescription products fell 4% on a mild flu season; animal health rose 7%.
- Net financial result was −€4.4 million, including a €9.7 million foreign exchange loss on the long rouble position.
- 2026 estimate raised: revenue €2,179 million (+7%) and net profit €439 million (+9%, €34 million above plan); capex just under €115 million.
- 2027 plan: revenue €2,308 million (+6%), net profit €474 million (+8%), investments €141 million, headcount +2%.
- Investments were €87.3 million (+31%); ten new products were added; employees 13,307.

### [Krka Group 1-9 2026 Business Performance Results Webcast (corrected transcript)](https://www.krka.biz/_assets/Krka-Group-1-9-2026-Results-Webcast-Transcript.pdf)

Executive talk · David Bratož, Member of the Management Board · 2026-11-13

- David Bratož (Management Board member) presented record 9M 2026 results on 13 November 2026: revenue €1,660 million (+8%), operating profit €456 million (+24%), EBITDA €528 million (+21%), net profit €364 million (+13%).
- "We are not only growing but growing more profitably": gross margin reached 60.8%, EBITDA margin 31.8%; he attributes the margin gain mainly to product mix (single-pill combinations, new launches, reformulated products), with only a partial rouble effect.
- Single-pill combinations: more than 200 launched, over 30% of Krka's total sales, approaching 40% in some markets.
- Russia is the largest market (+18% in euros), with local production supplying more than 70% of products sold there; Krka has been present "for more than 50 years".
- R&D: up to 10% of sales, more than 800 in-house experts, over 170 products in the pipeline; about 60% of R&D for new products, 40% for lifecycle management.
- The India plant is targeted for completion by end-2027, adding about 3 billion tablets a year of capacity; capex guidance was cut to around €115 million for 2026 because permits took longer.
- Guidance raised: 2026 revenue €2,179 million and net profit €439 million; 2027 plan €2,308 million revenue and €474 million net profit, with capex €141 million.
- Dividend €9.1 per share (27th consecutive increase), €31 million of buybacks in 9M and a new 3-year buyback programme for cancellation.

### [Krka Group FY 2025 Preliminary Business Performance Results Webcast (corrected transcript)](https://www.krka.biz/_assets/Krka-Group-FY-2025-Preliminary-Results-Webcast-Transcript.pdf)

Executive talk · David Bratož, Member of the Management Board · 2026-01-29

- David Bratož (Management Board member) presented FY2025 preliminary results and the 2026–2030 strategy on 29 January 2026: revenue above €2 billion for the first time (€2,041 million, +7%), EBITDA margin 27.4%, net profit up 13%.
- Russia was the top market at €422 million (+13%), with local production covering about 70% of sales; Poland grew 12% in value and 9% in volume; Ukraine flat at €96 million with 5% volume growth.
- The margin gain was driven "primarily by an improved product mix", partly supported by the rouble; net financial result €28 million.
- 2026 preliminary plan presented on the call: sales €2,144 million (+5%), net profit €405 million, capex €140 million.
- Strategy 2026–2030 is "not a revolution, it's rather an evolution": access to medicines, vertical integration, value creation; at least 5% growth and an EBITDA margin around 25%.
- Strategic updates: globalisation of capacities through joint ventures in India and China, supply reliability as a strategic asset, lifecycle management, entry into heart failure and obesity, and complex formulations and peptides.
- India JV with Laurus Labs (51/49) will add 3 billion tablets of capacity in its first phase; the China JV holds an EU GMP certificate.
- "We are a sales-driven company"; nearly 4,000 people in sales and marketing; "We don't chase sales at the cost of margins."

## Questions about Krka

### What does Krka do?

Krka develops, manufactures and sells generic prescription and non-prescription medicines and animal health products, and runs health resorts in Slovenia. It controls the chain from R&D and API production to its own sales network.

### What is Krka's revenue?

2025 revenue was €2,041.0 million (+7%), the first time above €2 billion, with net profit of €403.7 million. The 2026 estimate is €2,179 million.

### How many employees does Krka have?

13,307 employees at 30 September 2026, 42% of them outside Slovenia.

### What is Krka's strategy?

The 2026–2030 strategy targets at least 5% annual growth and an EBITDA margin of at least 25%, built on combination medicines, new areas such as heart failure and obesity, and capacity in India and China.

### Who leads Krka?

Jože Colarič has been President and CEO since 2005; the Management Board also includes Dr Aleš Rotar, Dr Vinko Zupančič and David Bratož.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
